Epilepsy & Seizures

The gold standard of cannabis evidence — FDA-approved CBD (Epidiolex) for rare childhood epilepsy syndromes.

Neurology Strong

What the research says

This is the strongest, most rigorous evidence cannabis has produced. Purified CBD (Epidiolex) was FDA-approved in 2018 for Dravet syndrome and Lennox-Gastaut syndrome after large placebo-controlled trials (the CARE trials) showed significant reductions in seizure frequency with an acceptable safety profile. It's a genuine, guideline-recognized antiseizure medication.

It's important to note the approved product is pharmaceutical-grade CBD — not the CBD oil sold in dispensaries, which varies wildly in dose and purity. The trials used measured doses of hundreds of milligrams of pure CBD, given on a schedule.

Minor cannabinoids are where the pipeline looks next. CBDV reached a Phase 2 add-on trial for focal seizures — it did not meet its primary endpoint, though it was well tolerated and some secondary measures showed signal. CBDVA inhibits T-type calcium channels, a mechanism relevant to seizure control, and CBCA showed anticonvulsant activity in a mouse model of Dravet syndrome. All of this is early or preclinical; none of it is a treatment today.

The honest caveats

This is the rare case where cannabis's evidence is genuinely 'Strong.' But it's about pharmaceutical CBD under medical supervision — not whole-flower, not THC (which can lower seizure threshold), and not self-dosing. For anyone with seizures, this is exclusively a clinician-guided conversation. CBD also interacts with common seizure drugs (especially clobazam), so doses must be managed carefully.

Compounds to explore

These are the compounds — terpenes and cannabinoids — that the research connects to this condition. They are starting points for reading a COA or choosing a product, not prescriptions. Each has its own guide with more detail.

Cannabinoid CBD Purified CBD (Epidiolex) is FDA-approved for Dravet and Lennox-Gastaut syndromes. Cannabinoid THC Not recommended — can lower seizure threshold in some people. Cannabinoid CBDV Reached a Phase 2 add-on trial for focal seizures — it did not meet its primary endpoint, though it was well tolerated. Cannabinoid CBDVA Inhibits T-type calcium channels, a mechanism relevant to seizure control — laboratory evidence. Cannabinoid CBCA Showed anticonvulsant activity in a mouse model of Dravet syndrome — early, preclinical data.

Sources for this condition

← Back to all conditions